IBR900 / Imbioray Bio - LARVOL DELTA

The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd.

New P1 trial • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

InBio completed nearly RMB 100 million in Series A+ financing, led by Huarui Investment [Google translation] (Sohu.com) - "According to the news from the investment community on January 22, Inbio (Hangzhou) Biopharmaceutical Co., Ltd...recently completed a round of A+ financing of nearly 100 million yuan. This round of financing was led by Huarui Investment, followed by Tailong Investment, Sunzi Technology, Huayi Capital, and Binjiang 5050 Fund. This round of financing is mainly used for the global FIC (first-in-class) universal natural killer cell therapy, that is, the registration clinical projects of innovative biological products such as IBR854, IBR733, IBR822, and IBR900, and to accelerate the launch of a series of original innovative peripheral blood-derived, non-viral vector, non-gene-edited spot universal immune-tamed NK/CAR-raNK and tiNK cell products."

Financing • Hematological Malignancies • Solid Tumor

A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=2 | Terminated | Sponsor: Beijing Boren Hospital | N=12 ➔ 2 | Trial completion date: Mar 2023 ➔ Aug 2022 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2022 ➔ Aug 2022; Research and development strategy adjustment

Combination therapy • Enrollment change • Oncolytic virus • Trial completion date • Trial primary completion date • Trial termination • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Lymphoma • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck